But Prime Minister Scott Morrison said Australia could afford the delay because it had almost no community transmission of Covid-19.
On Friday, he announced that Australia had doubled its Pfizer contract to 40 million doses.
But Australia so far has only received about one million Pfizer shots – with the rest to arrive “by the end of the year”, the government has said.
Australia also has a contract for 51 million Novovax vaccines, but it is yet to be approved by regulators.
Mr Morrison strongly urged people aged over 50 to continue with their vaccine, saying any risk was very rare.
“If an outbreak were to happen again… you would be putting yourself at risk if you didn’t get the vaccine, because you would be exposing yourself to the more likely event of a Covid-contracted condition that could result in serious illness,” he said.
Critics of Australia’s rollout have condemned the government for “putting all their eggs in one basket” with AstraZeneca.
The setback upends timelines for potential border reopenings, overseas travel and economic recovery.
A Vanderbilt spokesperson said Parton’s “generous” gift was helping “several promising research initiatives”.
A portion of the singer’s money went towards funding an early stage trial of the Moderna vaccine.
Her donation is also supporting a convalescent plasma study and research involving antibody therapies, Vanderbilt University Medical Center spokesperson John Howser said.
Convalescent plasma is used to treat people who are battling a Covid infection.
“Her gift provided support for a pilot convalescent plasma study that one of our researchers was able to successfully complete,” Mr Howser told BBC News.
“Funds from Dolly’s gift are also supporting very promising research into monoclonal antibodies that act as a temporary vaccine for Covid. Two of these antibodies are now being tested by a global pharmaceutical firm.”
Vanderbilt’s plasma pilot showed enough promise for the US NIH (National Institutes of Health) to step in with $34m (£26m) in additional support to conduct a national, multi-site clinical trial into the benefits of convalescent plasma.
Announcing her donation on Instagram in April, the star said: “My longtime friend Dr Naji Abumrad, who’s been involved in research at Vanderbilt for many years, informed me that they were making some exciting advancements towards that research of the coronavirus for a cure.
“I am making a donation of $1 million to Vanderbilt towards that research and to encourage people that can afford it to make donations
Appearing on NBC’s Today Show, the star added: “What better time right now, we need this. I felt like this was the time for me to open my heart and my hand, and try to help.”
He added: “She cares so much about helping others and we are very grateful for her ongoing support. These funds will help us complete promising research that can benefit millions in their battle with the virus.”
News about the world’s first successful trial of a coronavirus vaccine was greeted with jubilation on Monday.
But while there are a number of reasons to remain cautious, there’s at least one one big practical hurdle to overcome.
Speaking on Radio 4’s Today programme this morning, Health Secretary Matt Hancock spoke of the “mammoth logistical operation” of transporting the Pfizer/BioNTech vaccine from its point of manufacture to the arm of the patient.
That’s because it cannot be removed from a temperature of -70C (-94F) more than four times.
And that temperature is about four times as cold as the average home freezer.
Most other vaccines do not require anywhere near such low storage temperatures, so there is not a widespread infrastructure already in place.
In its own disclosure notice, Pfizer acknowledges there are “challenges related to our vaccine candidate’s ultra-low temperature formulation and attendant storage, distribution and administration requirements”.
At the Downing Street press conference on Monday, England’s deputy chief medical officer Prof Jonathan Van-Tam warned that even in normal times, “things can and do and have always gone wrong” when it comes to both vaccine manufacture and distribution.
How will it travel?
In the short-term, Pfizer has a plan.
The vaccine will be distributed from its own centres in the US, Germany and Belgium. It will need to travel both on land and by air, face potential storage in distribution centres in between stages and the final hurdle will be local delivery to clinics, surgeries, pharmacies, hospitals – anywhere the vaccine will be administered.
As revealed by the Wall Street Journal, Pfizer has developed a special transport box the size of a suitcase, packed with dry ice and installed with GPS trackers, which can keep up to 5,000 doses of the vaccine at the right temperature for 10 days, as long as it remains unopened. The boxes are also reusable.
Wiltshire-based firm Polar Thermals makes similar boxes for other vaccines and counts Pfizer among its clients, but not so far for this particular purpose.
The box is not likely to be cheap. Head of sales Paul Harrison says a standard chilled transport box, which will retain a temperature of up to -8C (not -80C) for five days and is big enough to hold 1,200 vaccines, costs about £5,000 per unit – although they can be re-used thousands of times.
His firm uses aerogel as insulation, rather than dry ice – which could come in handy if a global shortage of carbon dioxide from earlier this year continues to affect the availability of related products, of which dry ice is one.
The vaccine can survive for a further five days once thawed, Pfizer has said, but this does not buy a great deal of extra time.
In the longer-term, Public Health England says that in the UK “national preparations” are under way regarding both central storage and distribution of the vaccine across the country, but declines to give details.
As it stands, extreme cold storage is certainly not commonplace, and your local GP is unlikely to have it.
“We do not have fridges in general practice that go down to that sort of temperature,” GP professor Sam Everington told the BBC’s Newsnight programme on Monday. “So we will need them.”
And that issue is not exclusive to the UK. Dr Gregory Poland of the Mayo Clinic in Minnesota, told Reuters: “We’re a major medical centre and we don’t have storage capacity like this.”
Some institutions, such as universities and research labs, do have the right storage capacity. Is there a possibility they could be donated or lent out as temporary vaccination homes? In the UK, universities shared resources at the height of the first wave of the pandemic, including PPE-making equipment and ventilators.
“We may see existing fridges donated,” said Dr Michael Head, epidemiologist at the University of Southampton
The first effective coronavirus vaccine can prevent more than 90% of people from getting Covid-19, a preliminary analysis shows.
The developers – Pfizer and BioNTech – described it as a “great day for science and humanity”.
Their vaccine has been tested on 43,500 people in six countries and no safety concerns have been raised.
The companies plan to apply for emergency approval to use the vaccine by the end of the month.
A vaccine – alongside better treatments – is seen as the best way of getting out of the restrictions that have been imposed on all our lives.
There are around a dozen in the final stages of testing – known as a phase 3 trial – but this is the first to show any results.
It uses a completely experimental approach – that involves injecting part of the virus’s genetic code – in order to train the immune system.
Previous trials have shown the vaccine trains the body to make both antibodies – and another part of the immune system called T-cells to fight the coronavirus.
Two doses, three weeks apart, are needed. The trials – in US, Germany, Brazil, Argentina, South Africa and Turkey – show 90% protection is achieved seven days after the second dose.
Pfizer believes it will be able to supply 50 million doses by the end of this year, and around 1.3 billion by the end of 2021.
The UK should get 10 million doses by the end of the year, with a further 30 million doses already ordered.
However there are logistical challenges, as the vaccine has to be kept in ultra-cold storage at below minus 80C.
It has been an astounding feat to get this far so soon.
No vaccine has gone from the drawing board to being proven highly effective in such a short period of time.
And this vaccine seems to be even more effective than people were hoping.
There are still questions – how long does immunity last, does the vaccine work as well in high-risk elderly people, does it stop you spreading the virus or just from developing symptoms?
And the journey ahead is long and complicated.
Manufacturing enough doses and then actually immunising hundreds of millions of people around the world is a monumental challenge.
Hospital and care home staff will be prioritised along with those at highest risk from Covid-19.
So face masks and social distancing are likely to feature of our lives for some time to come.
But at last, the gloom of Covid is starting to give way to the hope that it might one day be over.
Dr Albert Bourla, the chairman of Pfizer, said: “We are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis.”
Prof Ugur Sahin, one of the founders of BioNTech, described the results as a “milestone”.
The data presented is not the final analysis. It is based on the first 94 volunteers to develop Covid – the precise effectiveness of the vaccine may change when the full results are analysed.
Pfizer and BioNTech say they will have enough safety data by the third week of November to take their vaccine to regulators. Until then it is not possible for countries to begin their vaccination campaigns.
But the companies’ announcement was welcomed as a significant development.
“This news made me smile from ear to ear,” Prof Peter Horby, from the University of Oxford.
“It is a relief… there is a long long way to go before vaccines will start to make a real difference, but this feels to me like a watershed moment.”
The UK Prime Minister’s official spokesman said the results were “promising” and that “the NHS stands ready to begin a vaccination programme for those most at risk once a Covid-19 vaccine is available
We use cookies to optimize our website and our service.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.